Platelet Rich Plasma and Hydrodissection for Carpal Tunnel Syndrome
Status:
Completed
Trial end date:
2019-10-30
Target enrollment:
Participant gender:
Summary
Carpal tunnel syndrome (CTS) is the most common peripheral entrapment neuropathy with
involving compression of the median nerve in the carpal tunnel. Rather than other progressive
disease, CTS is characterized by remission and recurrence. Although many conservative
managements of CTS, the effectiveness of these methods is insignificant or only persist for a
short duration. The platelet rich plasma (PRP) is a new and potential treatment for patients
with kinds of musculoskeletal disorders and recent reports showed being beneficial for
peripheral neuropathy in animal studies. Since 2014, three small clinical trials showed the
positive effect of PRP in peripheral neuropathy included CTSin a pilot research. However,
these studies have not entirely proved the effects of PRP on peripheral neuropathy because
these studies enrolled small number of patients and lacked controlled design. The
investigators design a randomized, double-blind, controlled trail to assess the effect after
ultrasound-guided PRP injection in patients with CTS.